PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. (Q52874022)
Jump to navigation
Jump to search
scientific article published on 8 September 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. |
scientific article published on 8 September 2014 |
Statements
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. (English)
1 reference
1 reference
1 reference
1 reference
Peter A Fasching
1 reference
Andreas Schneeweiss
1 reference
Sibylle Loibl
1 reference
Michael Untch
1 reference
Gunter von Minckwitz
1 reference
Stefan Paepke
1 reference
Annika Lehmann
1 reference
Mahdi Rezai
1 reference
Dirk M Zahm
1 reference
Fariba Khandan
1 reference
Holger Eidtmann
1 reference
Karel Dohnal
1 reference
Clemens Heinrichs
1 reference
Jens Huober
1 reference
Berit Pfitzner
1 reference
Fabrice Andre
1 reference
Judith L Lindner
1 reference
Christos Sotiriou
1 reference
August Dykgers
1 reference
Sanxing Guo
1 reference
Stephan Gade
1 reference
Valentina Nekljudova
1 reference
8 September 2014
1 reference
32
1 reference
3212-3220
1 reference
29
1 reference